Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4992632 | 0.84 | GYS1 (0.30) | HTR2AHTR2CHTR2B | |
| SCHEMBL18876067 | 0.81 | — | — | |
| SCHEMBL16004856 | 0.80 | HTR2A (0.30) | HTR2AHTR2CHTR2B | |
| SCHEMBL24947224 | 0.77 | HTR2A (0.36) | HTR2AHTR2CHTR2B | |
| SCHEMBL806491 | 0.76 | NQO1 (0.32) | — | |
| SCHEMBL789665 | 0.75 | HTR2A (0.32) | HTR2AHTR2CHTR2B | |
| SCHEMBL23206471 | 0.74 | DGAT1 (0.37) | — | |
| SCHEMBL5988324 | 0.73 | — | — | |
| SCHEMBL6305402 | 0.73 | HTR2A (0.32) | HTR2AHTR2CHTR2B | |
| SCHEMBL15280197 | 0.72 | HSP90AB1 (0.34) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20200281951-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
| US-10603331-B2 | Method of treating disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-03-31 | — | — | US | disclosed |
| US-20190142852-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-05-16 | — | — | US | disclosed |
| US-10064879-B2 | Method for treating depression and/or depression status with substituted quinoxaline compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-09-04 | — | — | US | disclosed |
| US-20170224713-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
| US-20160137633-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | AJINOMOTO CO., INC. (JP) | 2016-05-19 | — | — | US | disclosed |
| US-9290487-B2 | Pharmaceutical composition for treating diabetes | AJINOMOTO CO., INC. (JP) | 2016-03-22 | — | — | US | disclosed |
| US-20160058757-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMA CO LTD (JP) | 2016-03-03 | — | — | US | disclosed |
| EP-2616460-B1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE. | OTSUKA PHARMA CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| US-9090572-B2 | Substituted quinoxalines compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-28 | — | — | US | disclosed |
| US-20140336376-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | AJINOMOTO CO., INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| EP-2774917-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | Ajinomoto Co., Inc. (JP) | 2014-09-10 | — | — | EP | disclosed |
| US-20130261081-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 2013-10-03 | — | — | US | disclosed |
| WO-2013137479-A1 | DECAHYDROQUINOXALINE DERIVATIVES AND ANALOGS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-09-19 | — | — | WO | disclosed |
| EP-2616460-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE. | Otsuka Pharmaceutical Co., Ltd. (JP) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012036253-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE. | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336376-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | PPARG, GPR119, GYS2 | HTR2A 1553/4885HTR2C 1411/4885HTR2B 2268/4885 |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | HTR2A 32/4885HTR2C 5/4885HTR2B 17/4885 |
| US-20200281951-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | MC2R, SLC6A2, CRH | HTR2A 45/4885HTR2C 8/4885HTR2B 59/4885 |
| US-20170224713-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | HCRTR1, NPSR1, NTSR1 | HTR2A 58/4885HTR2C 46/4885HTR2B 74/4885 |
| US-20190142852-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | HCRTR1, NPSR1, NTSR1 | HTR2A 58/4885HTR2C 46/4885HTR2B 74/4885 |
| US-20160058757-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | HCRTR1, NPSR1, NTSR1 | HTR2A 54/4885HTR2C 44/4885HTR2B 76/4885 |
| US-10603331-B2 | Method of treating disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine | MC2R, PNMT, SLC6A2 | HTR2A 44/4885HTR2C 20/4885HTR2B 57/4885 |
| US-20160137633-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | PPARG, GPR119, GYS2 | HTR2A 1553/4885HTR2C 1411/4885HTR2B 2268/4885 |
| US-20130261081-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | MC2R, SLC6A2, CRH | HTR2A 45/4885HTR2C 8/4885HTR2B 59/4885 |
| US-10064879-B2 | Method for treating depression and/or depression status with substituted quinoxaline compounds | KYNU, CRH, CHRM1 | HTR2A 52/4885HTR2C 8/4885HTR2B 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.